Humatrope (Somatropin)

Humatrope is indicated for several endocrine conditions where growth hormone replacement is required.

• Growth hormone deficiency in children, to support normal linear growth
• Growth hormone deficiency in adults, to improve body composition and metabolic profile
• Turner syndrome-associated short stature, to increase final adult height
• Chronic renal insufficiency with growth failure, to promote growth when renal function is compromised
• Prader‑Willi syndrome related growth impairment, as part of a comprehensive management plan
• Idiopathic short stature in pediatric patients, when other causes have been excluded

• Humatrope delivers recombinant human growth hormone (somatropin) that binds to growth hormone receptors on target cells, primarily in liver and peripheral tissues. Receptor activation triggers the JAK2‑STAT5 signaling cascade, leading to increased transcription of insulin‑like growth factor‑1 (IGF‑1). Elevated IGF‑1 mediates anabolic effects on bone, cartilage, and muscle, while also influencing metabolism and protein synthesis, thereby restoring physiological growth hormone activity.

Adverse reactions to Humatrope vary in frequency and severity.

Common

• Mild injection‑site reactions such as pain, redness, swelling, or bruising that usually resolve within a few days
• Transient headache, dizziness, or nausea that are generally self‑limited and do not require intervention
• Temporary peripheral edema, particularly in the lower extremities, which may be intermittent and mild

Serious

• Intracranial hypertension presenting with persistent headache, nausea, vomiting, or visual disturbances, potentially leading to papilledema
• New‑onset diabetes mellitus or significant worsening of existing glucose intolerance, requiring monitoring of blood sugar levels
• Slipped capital femoral epiphysis, a painful hip condition in adolescents that may need orthopedic evaluation
• Severe allergic reactions, including rash, urticaria, angioedema, or anaphylaxis, which demand immediate medical attention
• Increased intracranial pressure causing visual field loss, papilledema, or other neurologic signs

Clinicians should consider several precautions before initiating Humatrope therapy.

• Not indicated for patients with active malignancy or a history of cancer due to potential tumor growth stimulation
• Caution in individuals with intracranial hypertension, as growth hormone may exacerbate the condition
• Monitor blood glucose regularly in patients with diabetes or risk factors for impaired glucose tolerance
• Assess thyroid function before and during treatment, since hypothyroidism can blunt response
• Evaluate for signs of slipped capital femoral epiphysis in growing children, especially during rapid growth phases
• Use with care in patients with severe renal or hepatic impairment, adjusting dose as recommended

Humatrope may interact with certain medications or substances, influencing its efficacy or safety profile.

Avoid

• Concomitant use of high‑dose glucocorticoids, which can antagonize the anabolic actions of growth hormone and diminish treatment efficacy.
• Simultaneous administration of insulin‑like growth factor‑1 (IGF‑1) therapy, which may potentiate hypoglycemia risk due to additive insulin‑like effects.

Use with caution

• Oral estrogen therapy, because estrogen can reduce the peripheral conversion of growth hormone to IGF‑1, lowering the expected growth response.
• Antidiabetic agents, since Humatrope may alter glucose homeostasis and require closer monitoring of blood‑sugar levels.
• Medications known to increase intracranial pressure, such as certain corticosteroids, which could exacerbate the risk of intracranial hypertension when combined with growth hormone.